Biotech Business - December 7, 2020
Single Technologies raises EUR 5 million
Single Technologies has announced the completion of an oversubscribed €5 million share issue to existing and new shareholders. Among the new investors are Jens von Bahr, Rothesay Ltd, Carl-Henric Svanberg funded Cygnus Montanus Trust, Professor Ulf Landegren and Andreas Ehn. Accelerate development of the 3-D sequencing platform The funds will be used to accelerate development […]
Financing - December 4, 2020
Senzime raises proceeds of approximately SEK 100 million
Senzime has successfully completed a directed issue of 4,545,000 shares, at a subscription price of SEK 22 per share, raising proceeds of approximately SEK 100 million. A number of Swedish and international institutional investors, including The Fourth Swedish National Pension Fund, Swedbank Robur Microcap, TIN Fonder, Handelsbanken Fonder, FE Småbolag Sverige and ÖstVäst Capital Management, […]
Business article - November 20, 2020
A new Swedish cell and gene therapy company has been launched
Elicera Therapeutics has announced that it has completed its first share issue and secured SEK 13.2 million in financing. The company is based on research by professor Magnus Essand’s research group at Uppsala University and will focus on CAR T-cells and oncolytic viruses. “In the CAR T-cell space, we have two drug candidates under development […]
Financing - October 27, 2020
QureTech Bio secures SEK 14 million investment
Venture capital company Nascent Invest has bought shares in Umeå-based QureTech Bio as part of a targeted new share issue. The multi-million SEK investment will provide long-term security for the Swedish life science company as it continues its work to discover and develop new solutions to combat antibiotic-resistant bacteria. “This investment means we can develop […]
Financing - October 19, 2020
Oncopeptides signs 40 million EUR loan agreement
Oncopeptides has entered into a loan agreement with the European Investment Bank (EIB), granting the company access to an unsecured loan facility of up to 40 million EUR. The loan may be used to further support the clinical development of melflufen, and the company’s transition from a R&D company into a fully integrated global biopharmaceutical […]
Biotech Business - October 6, 2020
Elicera Therapeutics has been launched and secures 13.2 MSEK
A new Swedish cell and gene therapy company, Elicera Therapeutics, has announced that it has completed its first share issue and secured 13.2 MSEK in financing. The company is based on research by professor Magnus Essand’s research group at Uppsala University and will focus on CAR T cells and oncolytic viruses. Four different drug candidates […]
